INPP4B (Inositol Polyphosphate-4-Phosphate Type II B)

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home Genes Leukemias Solid Tumors Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

INPP4B (Inositol Polyphosphate-4-Phosphate Type II B)

Written	2017-04	Hasan Huseyin Kazan, Ufuk Gunduz
		Department of Biological Sciences, Middle East Technical University, Ankara, hasanhuseyinkazan@gmail.com ((HHK); Department of Biological Sciences, Middle East Technical University, Ankara, Turkey; ufukg@metu.edu.tr (UG)

Abstract

Review on INPP4B, with data on DNA, on the protein encoded, and where the gene is implicated.

Keywords

Inositol Polyphosphate-4-Phosphate Type II B (INPP4B), tumor suppressor, PI3K/AKT pathway

(Note : for Links provided by Atlas : click)

Identity

HGNC (Hugo)	INPP4B
HGNC Previous name	inositol polyphosphate-4-phosphatase, type II, 105kD
	inositol polyphosphate-4-phosphatase, type II, 105kDa
LocusID (NCBI)	8821
Atlas_Id	43320
Location	4q31.21; Start: 142,023,160 bp End: 142,847,432 bp; 824.273 bases; Orientation: Minus strand [Link to chromosome band 4q31]
Location_base_pair	Starts at 142023160 and ends at 142846535 bp from pter ( according to hg19-Feb_2009) [Mapping INPP4B.png]
Local_order	From centromere to telomere: LINC02276, IL15, INPP4B, LOC07986194, LOC100287014.


	Local order of INPP4B. Local order is shown together with leading and subsequent genes on chromosome 4. The direction of arrows indicates transcriptional directions on the chromosome and arrow sizes approximate gene sizes.

Fusion genes
(updated 2017)

Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

DNA/RNA

Note	Human INPP4B gene is about 824 kb, localized at 4q31.1 and minus oriented. There are 27 exons of human INPP4B; the first four exons and a part of exon 5 form 5' untranslated region (UTR). A huge part of exon 27 constitutes 3' UTR (Croft et al., 2017). Mouse Inpp4b consists of 25 exons with the size of 45 to 1340 nucleotides. Two of those exons are 5' untranslated. The entire mouse Inpp4b gene is 600 kb. Gene locus is remarkably conserved between human and mouse (Ferron and Vacher, 2006).


	Numbers and illustrative sizes of exons of human INPP4B. Red boxes are the coding region and black boxes are the non-coding ones. Data adapted from Croft et al., 2017.

Transcription	In murine studies, an alternative-spliced form of cDNA, which was called Inpp4bαs and did not include exon 5 compared to Inpp4bα, was identified (Ferron and Vacher, 2006). There are three identified transcript variants of human INPP4B. Variant 1 has 27 exons; variant 2 and 3 have 26. Transcript variant 1 of human INPP4B is 4.590 bp; variant 2 is 8.984 bp and variant 3 is 9.083 bp (NCBI, NM_001331040.1; NM_001101669.2; NM_003866.3). Variant 1 and 2 encode the same isoform but their 5' untranslated region (UTR) differ from each other. Variant 3 contains an alternative 3' coding region and a novel 3' UTR compared to variant 1 (NCBI, 2017). Recently, Croft et al. isolated a novel variant of INPP4B, called INNP4B-S. This variant was shown to include an extra 27 bp from the sequence between exon 15 and 16, called exon 15A. Also, exons 20-24 were illustrated to be spliced compared to previous variants (Croft et al., 2017). ). In murine studies, transcription start site of Inpp4b was shown to be tissue specific (Ferron and Vacher, 2006). In human colon cancer cell lines, ETS1 was shown to regulate the expression of INPP4B by directly binding to promoter region of the gene (Guo et al., 2016).

Protein

Note	There are two isoforms of INPP4B protein, called INPP4Bα and INPP4Bβ (Billclif and Lowe, 2014). Mouse Inpp4bα cDNA encodes a 927 amino acid protein while Inpp4bβ cDNA encodes a 941 amino acid protein with a molecular weight of ~105 kDa which is the same with that of human INPP4B protein (Uniprot: O15327). INPP4B consists of an N-terminal C2-lipid binding domain, Nervy Homology 2 (NHR2) domain and a C-terminal dual phosphatase domain including a conserved Cys(X)₅Arg motif. NHR2 is responsible for oligomerization and protein-protein interaction (Agoulnik et al., 2011).



	Illustration of INPP4B protein. INPP4B protein consists of C2-lipid binding domain, Nervy Homology 2 (NHR2) domain and C-terminal dual phosphatase domain where conserved Cys(X)₅Arg motif locates. Data adapted from Agoulnik et al., 2011.

Expression	Inpp4bα has a broad tissue expression with higher levels in brain, skeletal muscle, lung, spleen, testis and thymus. Nevertheless, Inpp4bβ has a limited expression in brain, small intestine, skeletal muscle and heart (Ferron and Vacher, 2006).


	Expression profile of INPP4B in the tissues. INPP4B is moderately expressed in a numerous tissues including brain, muscles, pancreas, intestines, kidney, testis, prostate, breast and endometrium. Data taken from The Human Protein Atlas (http://www.proteinatlas.org) in April, 2017.

Localisation	Alpha form of INPP4B and INPP4B-S localize in cytoplasm while beta form mainly localize in Golgi apparatus (Ferron and Vacher, 2006; Billcliff and Lowe, 2014; Croft et al., 2017).
Function	Inositol polyphosphate 4-phosphate type II (INPP4B) is an enzyme responsible for phosphoinositide homeostasis. The major substrate for INPP4B is phophatidylinositol 3,4-biphosphate (PI(3,4)P₂). PI(3,4)P₂ is dephospharylated by INPP4B on D4 position and converted to phophatidylinositol 3-phosphate (PI(3)P). Those are critical secondary messengers in cells. Also, the substrate of INPP4B, PI(3,4)P₂ is necessary for the activation of AKT. Thus, INPP4B is a negative regulator of PI3K/AKT signaling pathway. AKT is a potent driver of tumorigenic cell growth. Hence, INPP4B was at first proposed as a tumor suppressor protein. However, INPP4B was illustrated to activate serum glucocorticoid-regulated kinase 3 ( SGK3), which also promotes cellular proliferation and growth, via production of PI(3)P and in turn could be oncogenic (Chi et al., 2015; Guo et al., 2016). INPP4B was also demonstrated to have a role in nerve conduction velocity (Lemcke et al., 2014) and regulation of osteoclast differentiation (Ferron et al., 2011; Vacher, 2013). Moreover, INPP4B was shown to dephosphorylate phosphotyrosine analogs, paranitrophenyl phosphate (pNPP) and 6,8-difluoro-4-methylumbelliferyl (DifMUP), pointing that INPP4B has a protein tyrosine phosphatase activity (Lopez et al., 2013).


	Functions of INPP4B protein. INPP4B dephosphorylates PI(3,4)P₂ to PI(3)P. PI(3,4)P₂ is a secondary messenger which is important for activation of AKT to promote cell proliferation, survival, migration and invasion. Thus, INPP4B proposed as a tumor suppressor. However, the product of INPP4B, PI(3)P was shown to trigger activation of SGK3 which also promotes those phenotypes. So, INPP4B was further proved to be oncogenic. Besides, INPP4B is fundamental for the regulation of nerve conduction velocity and osteoclast differentiation. Data adapted from Chew et al., 2015b.

Homology	Human and mouse INPP4B proteins share 96% identity. All mammalian INPP4B proteins include a Cys(X)₅Arg phosphatase catalytic site and a conserved C2 domain (Ferron and Vacher, 2006). C2 lipid binding domain of INPP4B is 91% identical between human and mouse (Agoulnik et al., 2011).

Mutations

Note

The C-terminal lipid phosphatase domain contains C ₈₄₂KSAKDRT (aa 842-849) motif which is conserved between type I and II phosphatases. Mutation of cysteine at position 842 to alanine in this motif causes INPP4B to unable to dephosphorylate phosphatidylinositols (Agoulnik et al., 2011). Also, K846M mutation resulted in loss of lipid phosphatase activity without affecting protein phosphatase activity and D847E mutation caused to loss of protein phosphatase activity and decrease in lipid phosphatase activity (Lopez et al., 2013). In a case study where samples from patients with gastric cancer (GC) and colorectal cancer (CRC) were used, an A7 repeat at the 25^th exon of INPP4B was analyzed. An identical frameshift mutation, through deletion of one base, in the A7 repeat region was identified in two CRCs (2/79: 2.5%) and one GC (1/34: 2.9%) patient (Choi et al., 2016).

Note	When firstly identified, INPP4B was proposed as a tumor suppressor especially when PTEN was deficient (Gewinner et al., 2009; Kofuji et al., 2015; Vo and Fruman, 2015); however, some studies proved that it could promote carcinogenesis.

Entity	Melanoma
Note	Chi et al. showed that INPP4B is upregulated in melanoma cell lines and human tissues. Even though INPP4B was shown to negatively regulate PI3K/AKT signaling and thus, it was thought to be tumor suppressor, INPP4B was demonstrated to be an oncogenic driver through activation of serum glucocorticoid-regulated kinase 3 (SGK3) and independently of AKT. INPP4B downregulation inhibited cell proliferation and tumor growth in xenograft while its overexpression caused enhanced cell proliferation and anchorage-independent growth of melanocytes (Chi et al., 2015). On the other hand, INPP4B expression was inversely correlated with tumor progression in melanocytic neoplasms (Perez-Lorenzo et al., 2014).


Entity	Colon Cancer
Note	INPP4B was demonstrated to be oncogenic and upregulated in human colon cancer cells and tissue. Silencing of INPP4B blocked the activation of AKT and SGK3, and inhibited cell proliferation and tumor growth in xenograft. Overexpression of INPP4B resulted in anchorage-independent growth of normal colon epithelial cells. Also, INPP4B was illustrated to dephosphorylate PTEN in colon cancer cells (Guo et al., 2016).


Entity	Thyroid Cancer
Note	Chew et al. showed loss of Innp4b in Pten heterozygous mice leaded to follicular thyroid carcinoma. INPP4B was also demonstrated to inhibit PI3K-C2 Endometrial Cancer α-mediated AKT2 activation in early endosomes in thyroid cancer cells (Chew et al., 2015). INPP4B was downregulated in human thyroid cancer cell lines and samples (Chew et al., 2015; Kofuji et al., 2015).


Entity	Endometrial Cancer
Note	INPP4B was demonstrated to be downregulated in samples from patients with endometrial cancer (Kofuji et al., 2015).


Entity	Prostate Cancer
Note	Hodgson et al. showed that activation of androgen receptor induced the expression of INPP4B via activation of corepressor, NCOR1, which regulates agonist-bound androgen receptor activity, and decreased the activation of AKT in prostate cancer cell lines. Also, INPP4B expression was shown to be down-regulated in samples from androgen-dependent prostate cancer (Hodgson et al., 2011). Same group also showed that de novo expression of INPP4B suppressed the invasion in vitro and in vivo in human prostate carcinoma cells due to that INPP4B regulated a wide range of genes associated with cell adhesion, extracellular matrix and cytoskeleton. It also inhibited metastases thanks to downregulating metastases-related BIRC5, phosphorylated PKC, expression of PKC in androgen-dependent and -independent manner and PTGS2 (COX-2). Moreover, de novo expressed INPP4B inhibited proinflammatory cytokine CXCL8 (IL-8) and induced PAK6 owing to downregulating PKC (Hodgson et al., 2014). In another study, overexpression of INPP4B in prostate cancer cell line, PC3, inhibited cell proliferation and decreased the levels of phosphorylated AKT (p-AKT), bringing about G1 arrest. Combination of INPP4B overexpression with PARP inhibitor, which arrested the cells in G2/M with an increase in p-AKT level, decreased the p-AKT levels and further inhibited the cell proliferation, suggesting that those combinations could be helpful for treatment of prostate cancer (Ding et al., 2014). INPP4B was also demonstrated to associate with the resistance to chemotherapeutics in prostate cancer. In docetaxel-resistant prostate cancer cell lines, INPP4B was shown to be downregulated. Overexpression of INPP4B resensitized the resistant cell lines towards docetaxel via inhibiting PI3K/AKT activation and expression of the mesenchymal markers fibronectin, N-cadherin, and vimentin, and upregulating the expression level of the epithelial maker E-cadherin (Chen et al., 2016).


Entity	Breast Cancer
Note	INPP4B was shown to be expressed in non-proliferative estrogen receptor (ER)-positive cells in normal breast tissue and ER-positive breast cancer cell lines. Nevertheless, ER-negative breast cancer cell lines did not express INPP4B. As a generalization, INPP4B expression was not seen in phosphatase and tensin homolog (PTEN)-null tumors. Down-regulation of INPP4B in ER-positive breast cancer cell lines increased AKT activation, cell proliferation and xenograft tumor growth while overexpression of INPP4B in ER-negative cell lines decreased the activated AKT and anchorage-independent growth (Fedele et al., 2010). Similarly, in triple negative breast cancer cell line, MDA-MB-231, stably overexpression of INPP4B inhibited cell proliferation and arrested the cell cycle at G1 phase through decreasing the level of phosphorylated AKT. By the combinational therapy approach, INPP4B expression was shown to increase the efficacy of poly-(adenosine diphosphate ribose) polymerase (PARP) inhibitor, AG014699 which is a DNA-damaging agent, arresting cell cycle at G2/M transition but could activate PI3K/AKT pathway (Sun et al., 2014). In a review article, Bertucci and Mitchell reported that INPP4B expression was lost in 84% of basal-like breast cancer; INPP4B loss of heterozygosity (LOH) occurs in 55% of triple negative and basal-like cancers, and 60% of BRCA1 mutant tumors as previously shown by Gewinner et al. (Gewinner et al., 2009; Bertucci and Mitchell, 2013). Similarly, INPP4B LOH was observed in 18.1% of Japanese breast cancer patients. Moreover, INPP4B LOH was significantly correlated with estrogen receptor (ER) and progesterone receptor (PR) negativity, higher nuclear grade, PTEN LOH and poorer prognosis (Tokunaga et al., 2016). In a case study where breast cancer samples from 43 patients were used, INPP4B expression was absent or low for 18% of cases. Low expression INPP4B was associated with larger tumor size and higher nuclear grade (Sueta et al., 2014). In another study, INPP4B was shown to prevent AKT activation but trigger the activation of SGK3, which was overexpressed and hyperactivated in breast cancer and caused to proliferation, invasive migration and tumorigenesis in breast cancer in vitro and in vivo models, via production of PI(3)P (Gasser et al., 2014).


Entity	Acute Myeloid Leukemia (AML)
Note	Dzneladze et al. showed that high levels of INPP4B in AML patients had poor response to induction therapy, shorter event-free survival and shorter overall survival. In cell culture, overexpression of INPP4B increased the colony formation potential, resulted in resistance to daunorubicin and ionizing radiation and supported phosphatase-dependent and AKT-independent proliferation. Hence, the researchers proposed INPP4B as an independent prognostic marker in AML (Dzneladze et al., 2015). Similarly, INPP4B was shown to be overexpressed in samples from patients with AML in another study. Overexpression of INPP4B in patients with AML resulted in reduced response to chemotherapy, early relapse and poor overall survival as figured out by Dzneladze et al. Moreover, overexpression of an inert variant of INPP4B, which did not display phosphatase activity, did not affect the resistance phenotype in vitro. However, silencing of INPP4B sensitized the AML cell lines towards chemotherapeutics, pointing a phosphoinositide phosphatase function-independent involvement of INPP4B in drug resistance in AML (Rijal et al., 2015).


Entity	Laryngeal Cancer
Note	In laryngeal cancer cell line, HEp-2, INPP4B expression was triggered by hypoxia and irradiation. Also, INPP4B overexpression enhanced aerobic glycolysis. It was demonstrated that one of the glycolysis-regulatory gene, hexokinase-2 (HK2) was regulated by INPP4B via AKT-mTOR pathway in this cell line. Silencing of both INPP4B and HK2 sensitized the radioresistant cells toward radiation and chemotherapeutic agents (Min et al., 2013). Moreover, INPP4B was demonstrated to be a marker of radioresistance in HEp-2 cells. INPP4B was shown to be overexpressed in radioresistant HEp-2 cells and that radiation or anticancer drug treatment induced INPP4B expression which was blocked by inhibition of extracellular signal-regulated kinase (ERK). INPP4B overexpression increased the resistance towards radiation and anticancer drugs and depletion of INPP4B re-sensitized the cells (Kim et al., 2012).


Entity	Nasopharyngeal Carcinoma (NPC)
Note	NPC is a viral-associated neoplasm where Epstein-Bar virus latent proteins affect multiple signaling cascades. Yuen et al. showed that INPP4B was downregulated in NPC cell lines compared to normal nasopharyngeal epithelial cell lines. The downregulation was demonstrated to become as a result of hypermethylation of the 5'CpG island of INPP4B (Yuen et al., 2014).


Entity	Lung Cancer
Note	In a case study where samples were obtained from 180 patients with non-small cell lung cancer subtypes, squamous cell carcinoma (SSC) or adenocarcinoma (ADCA), the ratio of INPP4B copy number was determined as 15% ≤1 copies, 62% 2 copies, and 23% ≥3 copies. Also, 47% displayed loss of loss of INPP4B expression which showed a strong correlation with SCC compared to ADCA (Stjernstrom et al., 2014). In another study, MIR937 which targeted INPP4B by directly binding to 3 UTR of INPP4B was upregulated in lung cancer cell line. Overexpression of miR-937 promoted anchorage-dependent and -independent growth while downregulation prevented these effects. Overexpression of miR-937 was shown to knockdown INPP4B which was proposed as the reason for increased growth rate in lung cancer cell lines (Zhang et al., 2016).


Entity	Bladder Cancer
Note	Hsu et al. developed ESR1 (estrogen receptor-α, ERα)--knockout mice to see the effect of ERα in bladder carcinogenesis. They showed that ERα reduced the carcinogen-induced malignant transformation ability. Moreover, ESR1 was demonstrated to control AKT activity via controlling the expression of INPP4B (Hsu et al., 2014).


Entity	Ovarian Cancer; Ovarian Teratomas (OTs) in particular
Note	Teratoma is a class of tumors that are composed of ecto-, meso- and endodermal tissues which are all foreign to the site of the origin. OTs are pathogenically activated non-ovulated germ cells-derived ovary tumors that exhibit disorganized pattern of cellular differentiation. Carriers of Rous sarcoma virus (RSV) Tgkd transgene are susceptible to teratomas. Tgkd transgene was demonstrated to be inserted into intergenic region of Inpp4b and Il15. This insertion was shown to affect Inpp4b expression and dysregulation of Akt pathway, promoting progression of ovarian teratomas (Balakrishnan and Chaillet, 2013). In ovarian cancer cells, INPP4B was illustrated to form a complex with BRCA1 and ATR which are the members of DNA repair mechanism. Loss of INPP4B, which was seen in 40% of patients with ovarian cancer studied, disrupted in BRCA1, ATM and ATR protein stabilities, resulting in DNA defects and sensitized the cells towards inhibitors of PARP, a nuclear enzyme sensing DNA single strand breaks and required for base excision repair (Ip et al., 2014).


Entity	Hepatocellular Carcinoma
Note	In hepatocellular carcinoma cell lines, MIR765 which directly targeted INPP4B was shown to be upregulated. Upregulation of miR-765 and in turn downregulation of INPP4B increased upregulation of p-AKT, CCND1 (Cyclin D1), and downregulation of p- FOXO3, p21 expression; thus it increased cellular proliferation and tumorigenicity. Downregulation of miR-765 rescued the phenotype in these cell lines via upregulation of INPP4B (Xie et al., 2016).


Entity	Osteoporosis
Disease	Osteoporosis is a genetic disease where bone mass is reduced because of dysregulation of osteoclast differentiation and maturation. Ferron et al. proposed Inpp4bα as a regulator of osteoclastogenesis. Inpp4bα was detected to be expressed from early osteoclast differentiation to activation. Moreover, phosphotase-inactivate Inpp4bα triggered the osteoclast activation. Inpp4bα was shown to control intracellular calcium level modulating NFATC1, which is a preosteoclast promoting transcription factor regulating osteoclast maturation, nuclear translocation and activation. Inpp4b-deficient mice displayed increased osteoclast differentiation rate, bringing about decreased bone mass and osteoporosis, and human INPP4B was proposed as a susceptibility locus for osteoporosis. Overall, Inpp4bα was regarded as a negative regulator of osteoclast differentiation (Ferron et al., 2011; Vacher, 2013).


Entity	Multiple Sclerosis (MS)
Disease	MS is a neurodegenerative and neuroinflammatory disease causing impairment of nerve conduction. In a genomic study, INPP4B was shown to regulate nerve conduction velocity. Moreover, an INPP4B polymorphism (rs13102150) was associated with MS cohorts (Lemcke et al., 2014).

	Nomenclature
HGNC (Hugo)	INPP4B 6075
	Cards
Atlas	INPP4BID43320ch4q31
Entrez_Gene (NCBI)	INPP4B 8821 inositol polyphosphate-4-phosphatase type II B
Aliases
GeneCards (Weizmann)	INPP4B
Ensembl hg19 (Hinxton)	ENSG00000109452 [Gene_View]
Ensembl hg38 (Hinxton)	ENSG00000109452 [Gene_View] ENSG00000109452 [Sequence] chr4:142023160-142846535 [Contig_View] INPP4B [Vega]
ICGC DataPortal	ENSG00000109452
TCGA cBioPortal	INPP4B
AceView (NCBI)	INPP4B
Genatlas (Paris)	INPP4B
WikiGenes	8821
SOURCE (Princeton)	INPP4B
Genetics Home Reference (NIH)	INPP4B
	Genomic and cartography
GoldenPath hg38 (UCSC)	INPP4B - chr4:142023160-142846535 - 4q31.21 [Description] (hg38-Dec_2013)
GoldenPath hg19 (UCSC)	INPP4B - 4q31.21 [Description] (hg19-Feb_2009)
GoldenPath	INPP4B - 4q31.21 [CytoView hg19] INPP4B - 4q31.21 [CytoView hg38]
ImmunoBase	ENSG00000109452
genome Data Viewer NCBI	INPP4B [Mapview hg19]
OMIM	607494
	Gene and transcription
Genbank (Entrez)	AI198719 AK298118 AK300891 AK302936 AY753912
RefSeq transcript (Entrez)	NM_001101669 NM_001331040 NM_003866
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)	INPP4B
Alternative Splicing Gallery	ENSG00000109452
Gene Expression	INPP4B [ NCBI-GEO ] INPP4B [ EBI - ARRAY_EXPRESS ] INPP4B [ SEEK ] INPP4B [ MEM ]
Gene Expression Viewer (FireBrowse)	INPP4B [ Firebrowse - Broad ]
Genevisible	Expression of INPP4B in : [tissues] [cell-lines] [cancer] [perturbations]
BioGPS (Tissue expression)	8821
GTEX Portal (Tissue expression)	INPP4B
Human Protein Atlas	ENSG00000109452-INPP4B [pathology] [cell] [tissue]
	Protein : pattern, domain, 3D structure
UniProt/SwissProt	O15327 [function] [subcellular_location] [family_and_domains] [pathology_and_biotech] [ptm_processing] [expression] [interaction]
NextProt	O15327 [Sequence] [Exons] [Medical] [Publications]
With graphics : InterPro	O15327
Splice isoforms : SwissVar	O15327
PhosPhoSitePlus	O15327
Domaine pattern : Prosite (Expaxy)	C2 (PS50004)
Domains : Interpro (EBI)	C2_domain_sf INPP4
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)	INPP4B
DMDM Disease mutations	8821
Blocks (Seattle)	INPP4B
Superfamily	O15327
Human Protein Atlas [tissue]	ENSG00000109452-INPP4B [tissue]
Peptide Atlas	O15327
HPRD	06322
IPI	IPI00022020 IPI00963837 IPI00922726 IPI00965101 IPI00964458 IPI00968221 IPI00029309 IPI00963881 IPI00966726 IPI00967550 IPI00968243 IPI00965363 IPI00965796
	Protein Interaction databases
DIP (DOE-UCLA)	O15327
IntAct (EBI)	O15327
BioGRID	INPP4B
STRING (EMBL)	INPP4B
ZODIAC	INPP4B
	Ontologies - Pathways
QuickGO	O15327
Ontology : AmiGO	protein binding cytoplasm cytosol phosphatidylinositol biosynthetic process signal transduction dephosphorylation phosphatidylinositol-3,4-bisphosphate 4-phosphatase activity phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity phosphatidylinositol-3-phosphate biosynthetic process inositol phosphate metabolic process
Ontology : EGO-EBI	protein binding cytoplasm cytosol phosphatidylinositol biosynthetic process signal transduction dephosphorylation phosphatidylinositol-3,4-bisphosphate 4-phosphatase activity phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity phosphatidylinositol-3-phosphate biosynthetic process inositol phosphate metabolic process
Pathways : KEGG	Inositol phosphate metabolism Phosphatidylinositol signaling system
REACTOME	O15327 [protein]
REACTOME Pathways	R-HSA-1855183 [pathway]
NDEx Network	INPP4B
Atlas of Cancer Signalling Network	INPP4B
Wikipedia pathways	INPP4B
	Orthology - Evolution
OrthoDB	8821
GeneTree (enSembl)	ENSG00000109452
Phylogenetic Trees/Animal Genes : TreeFam	INPP4B
HOGENOM	O15327
Homologs : HomoloGene	INPP4B
Homology/Alignments : Family Browser (UCSC)	INPP4B
	Gene fusions - Rearrangements
Fusion : Mitelman	FBXW7/INPP4B [4q31.3/4q31.21]
Fusion : Mitelman	KIAA0232/INPP4B [4p16.1/4q31.21]
Fusion Portal	FBXW7 4q31.3 INPP4B 4q31.21 LUSC
Fusion Portal	KIAA0232 4p16.1 INPP4B 4q31.21 BRCA
Fusion : FusionGDB	3.1.3.66
Fusion : Fusion_Hub	EGFLAM--INPP4B FBXW7--INPP4B GLS--INPP4B GRM8--INPP4B INPP4B--ALPK2 INPP4B--ARHGAP10 INPP4B--ARHGEF26 INPP4B--C9ORF3 INPP4B--ELL3 INPP4B--FAM120A INPP4B--FNDC3B INPP4B--GPX3 INPP4B--IST1 INPP4B--KDM4C INPP4B--LARP1B
	INPP4B--MAPK10 INPP4B--MCPH1 INPP4B--NIPAL2 INPP4B--NRP1 INPP4B--PALLD INPP4B--PLCZ1 INPP4B--RNF144A INPP4B--SLC25A14 INPP4B--TMBIM4 INPP4B--USP38 INPP4B--VPS54 INPP4B--WBSCR17 INPP4B--ZNF330 KIAA0232--INPP4B MAP9--INPP4B
	MAPK10--INPP4B PMEL--INPP4B RNF125--INPP4B SEC61A1--INPP4B SH3D19--INPP4B SKAP2--INPP4B SYNE2--INPP4B TMPRSS2--INPP4B
Fusion : Quiver	INPP4B
	Polymorphisms : SNP and Copy number variants
NCBI Variation Viewer	INPP4B [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)	INPP4B
dbVar	INPP4B
ClinVar	INPP4B
Monarch	INPP4B
1000_Genomes	INPP4B
Exome Variant Server	INPP4B
GNOMAD Browser	ENSG00000109452
Varsome Browser	INPP4B
Genetic variants : HAPMAP	8821
Genomic Variants (DGV)	INPP4B [DGVbeta]
DECIPHER	INPP4B [patients] [syndromes] [variants] [genes]
CONAN: Copy Number Analysis	INPP4B
	Mutations
ICGC Data Portal	INPP4B
TCGA Data Portal	INPP4B
Broad Tumor Portal	INPP4B
OASIS Portal	INPP4B [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMIC	INPP4B [overview] [genome browser] [tissue] [distribution]
Somatic Mutations in Cancer : COSMIC3D	INPP4B
Mutations and Diseases : HGMD	INPP4B
LOVD (Leiden Open Variation Database)	Whole genome datasets
LOVD (Leiden Open Variation Database)	LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)	LOVD 3.0 shared installation
BioMuta	search INPP4B
DgiDB (Drug Gene Interaction Database)	INPP4B
DoCM (Curated mutations)	INPP4B (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)	INPP4B (select a term)
intoGen	INPP4B
OncoKB	INPP4B
NCG6 (London)	select INPP4B
Cancer3D	INPP4B(select the gene name)
Impact of mutations	[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
	Diseases
OMIM	607494
Orphanet
DisGeNET	INPP4B
Medgen	INPP4B
Genetic Testing Registry	INPP4B
NextProt	O15327 [Medical]
TSGene	8821
GENETests	INPP4B
Target Validation	INPP4B
Huge Navigator	INPP4B [HugePedia]
snp3D : Map Gene to Disease	8821
BioCentury BCIQ	INPP4B
ClinGen	INPP4B
	Clinical trials, drugs, therapy
Protein Interactions : CTD	8821
Pharm GKB Gene	PA29883
Clinical trial	INPP4B
	Miscellaneous
canSAR (ICR)	INPP4B (select the gene name)
Harmonizome	INPP4B
DataMed Index	INPP4B
	Probes
	Litterature
PubMed	64 Pubmed reference(s) in Entrez
GeneRIFs	Gene References Into Functions (Entrez)
CoreMine	INPP4B
EVEX	INPP4B
GoPubMed	INPP4B

REVIEW articles	automatic search in PubMed
Last year publications	automatic search in PubMed